Latest news with #ActivePharmaceutical
Business Recorder
2 days ago
- Business
- Business Recorder
Local pharma industry: Govt urged to create conducive environment
ISLAMABAD: The All Pakistan Pharmaceutical Manufacturers Association (PPMA) has urged the government to create conducive environment for the local pharma industry so that it can enhance exports, create more jobs, and better serve the country. The pharma industry presented their demands to the Federal Minister for National Health Services and Regulations, Syed Mustafa Kamal, during a meeting here on Wednesday. Both the sides deliberated on key matters related to the pharmaceutical sector, including amendments in drug rules, indigenous production of Active Pharmaceutical Ingredients (APIs), and the expansion of export opportunities particularly in the context of bilateral collaboration with Afghanistan. During the meeting, the minister emphasised the government's commitment to fostering the local pharmaceutical manufacturing industry and reiterated the strategic importance of domestic API production. 'We must work jointly to ensure local production of APIs, not only to reduce reliance on imports and save valuable foreign exchange reserves, but also to unlock the export potential of our pharmaceutical products,' the minister stated. To advance this vision, the federal minister directed the Drug Regulatory Authority of Pakistan (DRAP) to develop a comprehensive concept note on the establishment of a Naphtha Cracker facility. This initiative aims to promote self-sufficiency in the production of essential raw materials for the pharmaceutical industry. Furthermore, the minister reaffirmed the government's resolve to eradicate the menace of counterfeit medicines from the market. 'We are introducing a modern trace and track system whereby a unique bar code will be printed on every medicine. This system will allow patients to verify the authenticity and retail price of any medicine using their mobile phones,' the minister added. The PPMA chairman highlighted that Pakistan's pharmaceutical exports currently stood over $450 million, but with government backing, this figure could cross $2 billion dollars within next two years. The minister acknowledged the immense potential for pharmaceutical exports, particularly in markets across South-West Asia and Central Asia. He encouraged the PPMA to submit a comprehensive proposal to enhance exports, assuring them that the ministry would provide the necessary support. The meeting concluded with a mutual understanding to strengthen public-private partnerships, streamline regulatory frameworks, and jointly pursue strategic initiatives to enhance pharmaceutical manufacturing, ensure medicine quality, and promote exports. Copyright Business Recorder, 2025
Express Tribune
2 days ago
- Business
- Express Tribune
Jam Kamal unveils new pharma export council
Listen to article Federal Minister for Commerce Jam Kamal Khan has reaffirmed the government's resolve to boost pharmaceutical exports, announcing the near-operational launch of PharmEx Pakistan — a new Pharma Export Promotion Council — under the Trade Development Authority of Pakistan (TDAP). "The pharmaceutical sector has huge export potential, and PharmEx Pakistan is just one or two steps away from becoming operational," the minister said on Wednesday, while praising the industry's rapid growth. He assured continued government support to help the sector meet international export targets. Speaking during a presentation by Pakistan Pharmaceutical Manufacturing Association (PPMA) Chairman Touqeerul Haq, the commerce minister also expressed optimism about trade with Afghanistan, noting that "with every passing day, our relations are growing stronger and more streamlined — pharmaceutical exports will rise accordingly." Haq briefed the commerce minister on PharmEx Pakistan, a new public-private initiative designed to manage and promote pharmaceutical exports. He credited the minister's swift action on urgent issues for preventing significant financial losses in the sector and projected that PharmEx Pakistan could help raise exports from $700 million to $3 billion. The push builds on steady sectoral growth. According to industry figures, pharmaceutical exports climbed from $270 million in 2020-21 to $355 million in 2024-25. PharmEx Pakistan is expected to improve regulatory compliance, expand international market access, and enhance global visibility for Pakistani pharmaceutical products. To further aid exporters, the commerce minister announced a dedicated Exporter Facilitation Desk within the ministry to address time-sensitive matters requiring direct government intervention. Separately, the federal minister for national health services met with a PPMA delegation to discuss critical sector issues, including amendments to drug rules, local production of Active Pharmaceutical Ingredients (APIs), and enhanced bilateral trade with Afghanistan. He stressed the importance of fostering the local pharmaceutical manufacturing industry and reiterated the strategic importance of domestic API production. The minister directed the Drug Regulatory Authority of Pakistan (DRAP) to develop a concept note on establishing a Naphtha Cracker facility, a key step toward self-sufficiency in pharmaceutical raw materials. To ensure drug quality, the health minister also announced a new trace and track system using barcodes for medicine verification via mobile phones.
Yahoo
2 days ago
- Business
- Yahoo
Ajinomoto Health & Nutrition North America, Inc. Opens Quality Control Laboratory Following $2.1M Renovation
RALEIGH, N.C., June 4, 2025 /PRNewswire/ -- Ajinomoto Health & Nutrition North America, Inc. (AHN), a global leader in amino acid manufacturing, celebrated the opening of its renovated Quality Control Laboratory today with a ribbon-cutting ceremony. Global senior leaders and dedicated team members who have been integral to the renovation efforts gathered at the modern facility on AHN's Raleigh, North Carolina, campus. The re-envisioned lab showcases AHN's commitment to delivering top product quality and leading safety standards. "By updating our facilities, we are even more equipped to meet the evolving needs of our customers and maintain our position as a leader in the industry," said Jessica Lee, Quality Manager. "Our Quality Control Laboratory is part of Ajinomoto Health and Nutrition's ongoing investment in quality and innovation." With the expanding need for amino acids in today's market, AHN's Quality Control Laboratory features advanced analytical equipment, improved workflow efficiencies, and enhanced safety measures. The facility benefits from Raleigh's skilled workforce, top universities, and numerous life sciences support companies, strengthening the area's reputation as a leading biotech hub. The enhancements also support AHN's growth plan for supplying Active Pharmaceutical Ingredient (API) amino acids and blends globally. By investing in these upgrades, AHN is positioning itself to meet the increasing global demand for high-quality APIs. The improved laboratory enables AHN to scale production and maintain stringent quality standards across larger volumes. This strategic investment aligns with AHN's long-term vision of expanding its market presence and reinforcing its reputation as a reliable supplier in the pharmaceutical industry. "The strategic investments made by AHN underscore our dedication to 'AminoScience,' the Ajinomoto Group's unique scientific approach to maximizing resources, resolving social issues, and contributing to people's wellbeing," says Ajinomoto Health & Nutrition's President and CEO, Ikuo Kira. The Ajinomoto Group connects its global divisions to deliver high-quality health and nutrition solutions by integrating research-based functions, technologies, and services centered on amino acids. About Ajinomoto Health & Nutrition North America, Inc. Ajinomoto Health & Nutrition North America, Inc. is a wholly-owned subsidiary of the Ajinomoto Group, a global leader in the research, development, manufacture, and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries, as well as food ingredients. The company opened its first U.S. office in New York in 1917 and has since grown and expanded its presence, establishing offices and production facilities in North Carolina, Iowa, Ohio, Massachusetts, and Illinois. Ajinomoto Health & Nutrition North America, Inc. leverages an international manufacturing, supply, and distribution chain to bring the highest-grade products to customers. For additional information on Ajinomoto Health & Nutrition North America, Inc., please visit Media contact: Charlotte Eby(515) 577-3171, ceby@ View original content to download multimedia: SOURCE Ajinomoto Health & Nutrition North America, Inc Sign in to access your portfolio
Business Upturn
14-05-2025
- Business
- Business Upturn
Zydus receives EIR from USFDA for its Ambernath API manufacturing facility
By Aman Shukla Published on May 14, 2025, 12:48 IST Zydus Lifesciences Ltd. has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facility located in Ambernath, Maharashtra. The inspection was conducted by the USFDA from February 10 to 14, 2025. Following the inspection, the facility received no observations , indicating full compliance with current Good Manufacturing Practices (cGMP). The USFDA has classified the outcome as No Action Indicated (NAI) , which is the most favorable classification for such inspections. In the exchange filing, the company shared, 'We wish to inform that the company has received the EIR report from the USFDA for the inspection conducted at its API manufacturing facility located at Ambernath, Maharashtra. This facility underwent an inspection from 10th to 14th February 2025, and had ended with NIL observations. The EIR report has classified it as No Action Indicated (NAI).' This successful outcome reinforces Zydus' strong commitment to maintaining global regulatory standards and ensuring quality manufacturing practices across all its facilities. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
The Star
27-04-2025
- Business
- The Star
Indian goods worth over US$10bil reaching Pakistan bypassing trade restrictions: Report
NEW DELHI: The economic think tank Global Trade Research Initiative (GTRI), amid the ongoing India-Pakistan tensions, said that the Indian goods worth over US$10 billion are reaching Pakistan every year indirectly through ports such as Dubai, Singapore, and Colombo, bypassing trade restrictions. GTRI said that Indian firms send goods to these ports, where an independent company offloads the consignment and keeps the products in bonded warehouses, where goods can be stored without paying duties while in transit. Speaking further, GTRI Founder Ajay Srivastava said, 'In the bonded warehouse, the labels and documents are modified to show a different country of origin. For example, Indian-made goods may be relabelled as 'Made in UAE'. After this change, they are shipped to countries like Pakistan, where direct trade with India is not allowed.' This method, he said, helps firms to bypass India-Pakistan trade restrictions; sell goods at higher prices, using the third country route; and avoid scrutiny, since the trade appears to come from other countries. In a separate development, reports have said that the Pakistani health authorities have initiated 'emergency preparedness' measures to secure pharmaceutical supplies in response to the suspension of trade ties with India. Pakistan relies on India for 30 per cent to 40 per cent of its pharmaceutical raw materials, including Active Pharmaceutical Ingredients (API) and various advanced therapeutic products. The report by Geo News has said that the Drug Regulatory Authority of Pakistan (DRAP) has confirmed that while there has been no formal notification regarding the ban's impact on the pharmaceutical sector, contingency plans are already in place. 'Following the 2019 crisis, we had started preparing for such contingencies. We are now actively looking at alternative avenues to meet our pharmaceutical needs,' the report quoted a senior DRAP official as saying. After the Pulwama terror attack in 2019, the two-way trade between India and Pakistan was already minuscule following steps taken by both sides. In April-January 2024-25, India's exports to Pakistan stood at US$447.65 million, while imports were meagre US$0.42 million. Exports and imports in 2023-24 were USD 1.18 billion and US$2.88 million, respectively. - The Statesman/ANN
